Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

loss) per share 

$
.00$
(0.08)Diluted net income (loss) per share 

$
.00$
(0.08)Shares used in computing basic net income (loss) per share 

66,82465,02769,40665,027Shares used in computing diluted net income (loss) per share CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)March 31, 2013December 31, 2012ASSETSCurrent assets:Cash and cash equivalents

$
,988$
95,779Accounts receivable, net

45,04643,999Inventory

78,23970,114Prepaid expenses and other current assets 

12,9079,448Total current assets

238,180219,340Property and equipment, net

59,99054,830Other non-current assets

745913Intangible assets, net

18,20718,767Goodwill

37,66037,694Total assets

$
354,782$
331,544LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable 

$
43,466$
33,701Accrued compensation 

15,92616,540Accrued royalties 

6,8597,992Accrued and other liabilities 

3,4724,235Current portion of deferred revenue

12,3549,599Current portion of notes payable

186183Total current liabilities 

82,26372,250Long-term portion of deferred revenue

1,0091,156Notes payable, less current portion

1,6411,685Other liabilities

8,5798,911Total liabilities

93,49284,002Shareholders' equity:Common stock

362,012355,867Additional paid-in capital 

123,806117,217Accumulated other comprehensive income

75756Accumulated deficit 

(225,285)(225,598)Total shareholders' equity 

261,290247,542Total liabilities and shareholders' equity 

$
354,782$
331,544 CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)Three Months Ended
March 31, 20132012Cash flows from operating activities:Net income (loss)<
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
2. Cepheid Announces Board of Directors Changes
3. Cepheid Reports 2012 Second Quarter Results
4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. Cepheid Welcomes Senior Vice President of Human Resources
11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... 2015 Australian prostate cancer technology company Minomic ... prize recognising ,outstanding, science that uses its patented antibody. ... a novel prostate cancer diagnostic test known as MiCheck® ... taking out the peer-reviewed Australian Museum Eureka Science Prize ... This prize is awarded for ground breaking research ...
(Date:9/2/2015)... 2, 2015 BioLight Life ... the "Company"), a firm that invests in, manages ... diagnostics, announced today that presentations highlighting its IOPtiMate™ ... delivered at the Ophthalmology Futures European Forum and ... Cataract & Refractive Surgeons ("ESCRS"), both taking place ...
(Date:9/2/2015)... California (PRWEB) , ... September 02, 2015 , ... ... a critical demand to aid high-risk surgeries. From vital sign monitoring in ICU ... by Intel technology enables surgeon to make real-time clinical decisions with simultaneous access ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3
... Point of Preventing Bacterial Colonization with ... Leader, VANCOUVER, March 18 /PRNewswire-FirstCall/ - ... ANP), a global specialty pharmaceutical and,medical device ... from its 960,patient clinical trial comparing its ...
... RainDance Technologies, Inc.,a developer of NanoReactor ... Stephen E. Becker as Vice President,Commercial Officer, ... responsible for continuing the growth of the,company,s ... launch of its first,life science offering," said ...
... AAAAI 64th Annual Meeting also show that C1-INH is ... HAE attacks across all body sites, PHILADELPHIA, March ... effective therapy that rapidly relieves acute,abdominal and facial swelling ... serious genetic disorder, according to data,presented today at the ...
Cached Biology Technology:960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 2960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 3960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 4960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 5960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 6960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter 7RainDance Appoints Becker Chief Commercial Officer 2RainDance Appoints Becker Chief Commercial Officer 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 2C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 3C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study 4
(Date:8/5/2015)... ALBANY, New York , August 5, 2015 /PRNewswire/ ... new market report titled "Facial Recognition Market - Global ... - 2022", the global market for facial recognition is ... market is driven by increased demand for surveillance systems ... to the rising number of crimes and terrorist activities ...
(Date:8/4/2015)... -- AMRI (NASDAQ: AMRI ) today reported financial and operating results ... , Second quarter contract revenue of $ 85.2 ... Adjusted contract margins of 26 % , ... decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, with ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... redundant portions of the fruit fly genome may not ... from a Princeton-led team of researchers suggest that repeated ... normal development under less-than-ideal growth conditions by making sure ... appropriate times. If similar regions are found in humans, ...
... estimated to afflict as many as 12 million people worldwide ... vulnerable to compounds developed to treat cancer and other disorders, ... have found. Scientists searched the genome of the parasite ... of TOR kinases, proteins that are linked to cell growth ...
... SPOKANE, Wash.Washington State University researchers have discovered a way to ... for slowing and even stopping the growth of tumors. "Hopefully, ... Weihang Chai, an assistant professor in the WSU School of ... "Basically, you make the cancer cell go from immortal to ...
Cached Biology News:Redundant genetic instructions in 'junk DNA' support healthy development 2Redundant genetic instructions in 'junk DNA' support healthy development 3Redundant genetic instructions in 'junk DNA' support healthy development 4Cancer drugs may help stop major parasite 2
B3-1...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Biology Products: